Search
Clofarabine
go.drugbank.com/drugs/DB00631ApprovedInvestigationalClofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. … It is not known if the drug extends life expectancy. Its potential use in acute myeloid leukaemia (AML) and juvenile myelomonocytic leukaemia (JMML) has been investigated.
Daridorexant
go.drugbank.com/drugs/DB15031ApprovedInvestigational[A244225] It was approved by the FDA on January 10, 2022, under the name QUVIVIQ.[L39660] as the second orexin receptor antagonist approved to treat insomnia following [suvorexant]. … Daridorexant was designed via an intensive drug discovery program to improve the potency and maximize the duration of action while minimizing next-morning residual activity.
Molybdenum
go.drugbank.com/drugs/DB11137ApprovedInvestigationalWhen complexed with Technetium Tc 99m, molybdenum is used as a radiopharmaceutical agent in diagonistic procedures.
Mixtures: Venexa FE, Ribotin-ENintedanib
go.drugbank.com/drugs/DB09079ApprovedInvestigational[L8453] Within the spectrum of idiopathic pulmonary fibrosis treatment options, nintedanib is currently one of only two disease-modifying therapies available and indicated for the condition (the other … being [Pirfenidone]) and as such is used as a first-line treatment following diagnosis to slow down the progressive loss of lung function.
Deucravacitinib
go.drugbank.com/drugs/DB16650ApprovedInvestigational[A246943] Deucravacitinib was first approved by the FDA in September 2022 to treat moderate-to-severe plaque psoriasis. … Unlike other Janus kinase 1/2/3 inhibitors that bind to the conserved active domain of these non-receptor tyrosine kinases, deucravacitinib binds to the regulatory domain of TYK2 with high selectivity
Meropenem
go.drugbank.com/drugs/DB00760ApprovedInvestigationalThe treatment aims to resolve infection-related symptoms and achieve negative urine culture, where the infections are proven or strongly suspected to be caused by susceptible bacteria. … Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of vital cell wall components, which leads to cell death.
Products: MAXIPEN 500 MG IV ENJEKSIYON VE INFÜZYON IÇIN TOZ IÇEREN FLAKON, MERAPARON 1 G IV ENJEKSİYON VE İNFÜZYON İÇİN TOZ İÇEREN FLAKON, 1 ADETRamelteon
go.drugbank.com/drugs/DB00980ApprovedInvestigationalRamelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). … Ramelteon has not been shown to produce dependence and has shown no potential for abuse.
Trimetazidine
go.drugbank.com/drugs/DB09069ApprovedInvestigationalTrimetazidine is a piperazine derivative indicated for the symptomatic treatment of stable angina pectoris in patients inadequately controlled or intolerant to first line therapies. … [A233215] The increased intracellular calcium decreases contractility.
Methoxyflurane
go.drugbank.com/drugs/DB01028ApprovedInvestigationalVet approvedWithdrawnIf so employed, it should be administered with nitrous oxide to achieve a relatively light level of anesthesia, and a neuromuscular blocking agent given concurrently to obtain the desired degree of muscular … (From AMA Drug Evaluations Annual, 1994, p180) In the US, methoxyflurane is one of the products that have been withdrawn or removed from the market for reasons of safety or effectiveness.[L43942]
Tocopherol
go.drugbank.com/drugs/DB11251ApprovedInvestigationalThe classification of the tocopherol molecules is designated depending on the number and position of the methyl substituent in the chromanol ring. … The different types of tocopherol can be presented trimethylated, dimethylated or methylated in the positions 5-, 7- and 8-.
Categories: Vitamin E, tocopherol (vit E)Products: VITAMINA E VCA